What is AllCells?
AllCells operates as a specialized provider of human primary cells and whole tissue products, catering to the rigorous requirements of medical, scientific, and academic research institutions. The company's portfolio, which includes cryopreserved and fresh leukopaks, bone marrow, and cord blood, is essential for bio-manufacturing organizations focused on the development of advanced therapies. Through a commitment to stringent donor management and GMP-compliant custom cell isolation services, AllCells ensures that researchers have access to the high-fidelity biological inputs necessary for the next generation of cell and gene therapy breakthroughs.
How much funding has AllCells raised?
AllCells has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in AllCells
PPP
Public-Private Partnership
What's next for AllCells?
With this major enterprise-level funding, AllCells is well-positioned to scale its infrastructure to meet the burgeoning needs of the cell and gene therapy sector. The strategic allocation of this capital will likely focus on expanding donor networks and enhancing the precision of their isolation technologies to maintain a competitive edge in a rapidly evolving market. As the industry shifts toward more complex therapeutic modalities, the company's ability to provide reliable, compliant, and timely biological materials will remain a key driver of its long-term growth trajectory and market influence.
See full AllCells company page
